- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03713658
A Study to Evaluate the Ability of Conducting a Study of Oral Risperidone Followed by Paliperidone Palmitate in Rwandan Healthcare Facilities
February 28, 2024 updated by: Janssen Research & Development, LLC
A Pilot-Study in Rwandan Health Care Settings to Examine the Feasibility of a Large Pragmatic Clinical Study to Assess the Value of Paliperidone Palmitate in Rwanda
The purpose of this study is to evaluate the feasibility of conducting a study of oral risperidone followed by paliperidone palmitate for once monthly (PP1M) and paliperidone palmitate for every 3 months (PP3M) in rwandan healthcare facilities with mental healthcare capabilities.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
- Drug: Risperidone 3 mg
- Drug: Paliperidone Palmitate 50 mg eq.
- Drug: Paliperidone Palmitate 75 mg eq.
- Drug: Paliperidone Palmitate 100 mg eq.
- Drug: Paliperidone Palmitate 150 mg eq.
- Drug: Paliperidone Palmitate 175 mg eq.
- Drug: Paliperidone Palmitate 263 mg eq.
- Drug: Paliperidone Palmitate 350 mg eq.
- Drug: Paliperidone Palmitate 525 mg eq.
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Kigali, Rwanda, 423
- CARAES Ndera Neuro-Psychiatric Hospital
-
Musanze District, Rwanda, 57
- Ruhengeri Referral Hospital, Public Hospital
-
Ngoma District, Rwanda, 10
- Kibungo Referral Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Participants with diagnosis of schizophrenia by mini international neuropsychiatric interview (MINI)- Screen/ MINI (Module K) that requires treatment initiation or a change in treatment to better address safety or efficacy limitations of current treatment
- Participants at least moderately ill as measured by the clinical global impressions - severity of schizophrenia (CGI-SS) scale for schizophrenia, or experiencing poorly tolerated side effects from their current medications, or having difficulty with adequate adherence to treatment, per the investigator's judgement
- Participants have a primary caregiver who is willing to participate in this study (caregiver should be knowledgeable about the participant's condition and is expected to be with the participant for greater than (>) 24 hours each week for the duration of the study)
- Participants able to give consent to participate in a clinical study that includes treatment with risperidone and long-acting injectable formulations of paliperidone palmitate. Participants must be willing to receive injections. The participant and the caregiver participant must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
- Participants must be willing and able to provide responses for all self-administered questionnaires
Exclusion Criteria:
- Participants have a physical, mental, or legal incapacity that prevents a valid consent or capacity to complete about 12 months of treatment with antipsychotic medication and compliance with this study protocol
- Participants with history of organic brain syndromes, comorbid psychiatric and/or physical illnesses, or significant comorbid substance abuse that is likely to interfere with understanding of or compliance with study requirements
- Participants with known allergies, hypersensitivity, or intolerance to risperidone or paliperidone palmitate or their excipients
- Participants with poor prior response to risperidone
- Participants who received an investigational medication (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study medication, or is currently enrolled in an investigational study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Oral Risperidone
Participants will receive 3 milligram (mg) oral risperidone tablets once daily for up to one Week to determine tolerability based on investigator review.
|
Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
|
Experimental: Paliperidone Palmitate Once Monthly (PP1M)
Participants will receive 50, 75, 100 or 150 mg eq.
([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate once monthly (PP1M) intramuscular injection for 4 months (17 weeks) plus option to continue 3 more months if not stabilized depending on the participant's clinical safety, tolerability and efficacy requirements.
|
Participants will receive 50 mg eq.
PP1M intramuscular injection for 17 Weeks.
Other Names:
Participants will receive 75 mg eq.
PP1M intramuscular injection for 17 Weeks.
Other Names:
Participants will receive 100 mg eq.
PP1M intramuscular injection for 17 Weeks.
Other Names:
Participants will receive 150 mg eq.
PP1M intramuscular injection for 17 Weeks.
Other Names:
|
Experimental: Paliperidone Palmitate Every 3 Months (PP3M)
Participants will receive 175, 263, 350 or 525 mg eq.
([paliperidone palmitate] mg equivalent [to paliperidone]) long acting formulation of paliperidone palmitate every 3 months (PP3M) intramuscular injection for 24 Weeks.
|
Participants will receive 175 mg eq.
PP3M intramuscular injection for 24 Weeks.
Other Names:
Participants will receive 263 mg eq.
PP3M intramuscular injection for 24 Weeks.
Other Names:
Participants will receive 350 mg eq.
PP3M intramuscular injection for 24 Weeks.
Other Names:
Participants will receive 525 mg eq.
PP3M intramuscular injection for 24 Weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Successful Completion of Study Procedures
Time Frame: Up to Week 46
|
Percentage of participants with successful completion of study procedures related to diagnosis and outcome measures assessment will be reported.
|
Up to Week 46
|
Percentage of Participants With Successful Delivery of Risperidone/PP1M/PP3M for the Duration of the Study
Time Frame: Up to Week 46
|
Percentage of participants with successful delivery of risperidone/PP1M/PP3M for the duration of the study will be reported.
|
Up to Week 46
|
Percentage of Participants With Successful Administration of Risperidone/PP1M/PP3M Throughout the Study
Time Frame: Up to Week 46
|
Percentage of participants with successful administration of risperidone/PP1M/PP3M throughout the study will be reported.
|
Up to Week 46
|
Quality of Life as Assessed by World Health Organization Quality of Life Scale Brief Version (WHO QoL-BREF) Total Score
Time Frame: Up to Week 46
|
The WHO QoL-BREF is a 25 item scale used to assess the quality of life.
All items are rated on a five-point likert scale using response categories such as 1 represents very poor and 5 represents very well with a possible maximum score of 125 and a minimum score of 25.
|
Up to Week 46
|
Clinician Satisfaction as Assessed by Clinician Satisfaction Rating Scale Score
Time Frame: Up to Week 46
|
The Clinician Satisfaction Rating is a 4-item scale.
Two items use a Likert scale with a six-point range from 0 (definitively not) to 6 (definitely) and two items are multiple-choice (example, "select all that apply").
The scale will be used to assess the acceptability and/or burden for the provider associated with the study including treatment with long-acting injectables (LAIs).
|
Up to Week 46
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Met Mini-International Neuropsychiatric Interview (MINI)-MINI Screen and Module K Criteria
Time Frame: Up to Week 46
|
The MINI-Screen is a structured and standardized diagnostic interview used to determine the most common psychiatric disorders according to axis I diagnostic and statistical manual of mental disorders-fourth edition text revision (DSM-IV-TR) and the international classification of diseases and related health problems (ICD-10).
The MINI-screen will be administered to participants for preselection by a qualified psychiatric professional.
If this step is passed, then Module K of MINI will be applied by a medical doctor (preferably a psychiatrist) or a psychologist in order to confirm the diagnosis of schizophrenia and to determine if there are other psychiatric conditions present.
Number of participants who met MINI criteria will be assessed.
|
Up to Week 46
|
Number of Participants Intended to Complete/Attend Next Visit as Assessed by Intent-to-Attend (ITA) Plus Assessment Scale
Time Frame: Up to Week 46
|
The ITA-Plus scale is a single Likert scale question with a range of 0 indicates definitely not attending to 6 indicates definitely attending that will be used to estimate the likelihood of completing the study or attending the next visit to provides qualitative feedback on why completion/attendance may not occur.
Number of participants intended to complete/attend next visit will be assessed.
|
Up to Week 46
|
Direct Cost Assessment of Schizophrenia Care as Assessed by Client Service Receipt Inventory (CSRI) Scale Score
Time Frame: Up to Week 46
|
The CSRI scale will be used to assess the costs of schizophrenia care for participants, caregivers, and health care providers, especially direct costs.
|
Up to Week 46
|
Indirect Cost Assessment of Schizophrenia Care as Assessed by Cost Assessment Questionnaire (CAQ)
Time Frame: Up to Week 46
|
The CAQ will be used to assess the costs of schizophrenia care for participants, caregivers, and health care providers, especially indirect costs.
|
Up to Week 46
|
Change From Baseline in Sheehan Disability Scale (SDS) Total Score
Time Frame: Baseline up to Week 46
|
SDS will be used to assess the functioning of participants with schizophrenia.
It has participant-reported outcome measure and 5 item questionnaire used for assessment of functional impairment and associated disability.
First three items assess disruption of 1 work/school, 2 social life, 3 family life/home responsibilities using a 0 (no impairment) - 10 (most severe impairment).
Score for first 3 items are summed to create total score of 0-30 where higher score indicates greater impairment and a negative change in score indicates improvement.
|
Baseline up to Week 46
|
Number of Participants With Adverse Events (AEs) as a Measure of Safety
Time Frame: Up to Week 46
|
Safety will be assessed by AEs along with concomitant medications, past medical history, and demographics of participants who will participate in this study.
An adverse event is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product.
An adverse event does not necessarily have a causal relationship with the medication.
An adverse event can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product.
|
Up to Week 46
|
Psychosis as Assessed by Mental Illness With Lay Evidence (SMILE) Scale Score
Time Frame: Up to Week 46
|
The Psychosis module of the SMILE will be used to assess the clinical symptoms of schizophrenia.
It is a 15-item Likert scale covering questions to describe participants condition like if they have kept the body neat and clean, difficulty in completing routine tasks, talked to themselves etc with answers on a point range of 0 (Never) to 5 (All the time).
It uses 7-day recall period.
Both the participant and caregiver participant will complete this scale.
|
Up to Week 46
|
Clinical Global Impression - Severity of Schizophrenia (CGI-SS) Scale Total Score
Time Frame: Up to Week 46
|
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia.
It is a single-item Likert scale with a 7-point range (0 indicates none to 7 indicates extreme symptoms).
|
Up to Week 46
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 18, 2018
Primary Completion (Actual)
December 2, 2019
Study Completion (Actual)
December 2, 2019
Study Registration Dates
First Submitted
October 18, 2018
First Submitted That Met QC Criteria
October 18, 2018
First Posted (Actual)
October 22, 2018
Study Record Updates
Last Update Posted (Actual)
March 1, 2024
Last Update Submitted That Met QC Criteria
February 28, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Schizophrenia
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin 5-HT2 Receptor Antagonists
- Serotonin Antagonists
- Dopamine D2 Receptor Antagonists
- Dopamine Antagonists
- Paliperidone Palmitate
- Risperidone
Other Study ID Numbers
- CR108551
- R092670PSY4001 (Other Identifier: Janssen Research & Development, LLC)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency.
As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Peking UniversityNot yet recruitingTreatment-resistant Schizophrenia
-
Rakitzi, StavroulaActive, not recruiting
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
Clinical Trials on Risperidone 3 mg
-
Rovi Pharmaceuticals LaboratoriesCompletedSchizophrenia | Schizoaffective DisorderSpain, South Africa, Russian Federation, Croatia
-
Janssen-Cilag S.p.A.CompletedSchizophrenia | Schizoaffective Disorder
-
Rovi Pharmaceuticals LaboratoriesCompletedAcute SchizophreniaUnited States, Ukraine
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Rovi Pharmaceuticals LaboratoriesCompletedSchizophreniaUnited States, Ukraine
-
Rovi Pharmaceuticals LaboratoriesRecruiting
-
Janssen-Cilag International NVActive, not recruiting
-
Autoimmune Technologies, LLCCompleted
-
University College, LondonActive, not recruitingObesity | Diabetes | Metabolic SyndromeUnited Kingdom
-
Serum Institute of India Pvt. Ltd.PPDCompleted